Project Grant F32AI194808
- This Project Grant award of $305,000.00 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to investigate the role of stem-like T cells in multiple sclerosis (MS) disease progression. The key objectives are to: Rigorously test the hypothesis that a continuing stemness and differentiation of CD4+ T stem cells results in functional and transcriptomic diversification under evolving...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $104,433 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to The Washington University in St. Louis to conduct research on examining microglia reactivation in multiple sclerosis (MS). The project aims to define the gene signature of disease-associated microglia (DAM) and understand how the function of these cells is affected by repeated activation, as...
- This $687,422 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) to the Benaroya Research Institute at Virginia Mason supports research to characterize CD4+ tissue resident memory T cells in the context of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). The key objectives are to: 1) establish the diversity and specialization of CD4+ tissue resident memory T cells...
- This $198,928 Project Grant was awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The grant will support research at the University of California, San Francisco to elucidate the cellular mechanisms underlying central nervous system injury and progression in multiple sclerosis. Key objectives include determining the role of astrocyte response,...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, is providing $426,938 to Virginia Commonwealth University to explore the role of a novel glutamate-driven signaling pathway initiated in maturing oligodendrocytes through the glutamate transporter GLT-1/EAAT2. This research aims to characterize the mechanisms downstream of...
- This Project Grant award in the amount of $521,839.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program. The grant supports research at the University of California, San Diego to investigate the molecular mechanisms underlying the activation of microglia, which contribute to oxidative stress and tissue damage in multiple sclerosis (MS)....
- This $614,009 federal Project Grant award was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research into the molecular mechanisms of oligodendrocyte myelination and remyelination, which are critical processes for addressing demyelinating diseases of the central nervous system like multiple sclerosis. The awardee, Children's Hospital...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (CFDA 93.853: Extramural Research Programs in the Neurosciences and Neurological Disorders) provides $424,234 to The Leland Stanford Junior University to conduct research on in vivo tracking of innate immune activation and therapeutic response in mouse models of multiple sclerosis (MS) using the PET radiotracer [18F]OP-801. The research aims to leverage this novel radiotracer to obtain real-time molecular...
- This $549,256 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research by Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System, to study how the CLEC16A gene regulates astrocyte responses in central nervous system inflammation. The research aims to elucidate the mechanisms by which CLEC16A-driven...
- This $233,250 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program will fund research at The Washington University to investigate the potential of hyperpolarized 13C magnetic resonance spectroscopic imaging (HP 13C MRSI) and ultra-short echo time magnetization transfer (UTE-MT) imaging to non-invasively study the role of lactate metabolism and...
CYSTATIN F EXPRESSION ON MICROGLIA IS CRITICAL FOR CONSTRAINING DEMYELINATION FOLLOWING VIRAL INFECTION OF THE CENTRAL NERVOUS SYSTEM - PROJECT SUMMARY MULTIPLE SCLEROSIS (MS) IS A DEBILITATING AUTOIMMUNE DISEASE WHEREIN ACTIVATED IMMUNE CELLS MISTAKENLY ATTACK THE PROTECTIVE MYELIN COATING ON NEURONS. THIS RESULTS IN SCARRING AND THE FORMATION OF LESIONS IN THE BRAIN AND/OR SPINAL CORD THAT CONTRIBUTE TO A HOST OF SYMPTOMS THAT VARY DEPENDENT ON THE LOCATION OF THE INJURY. THE PRECISE ETIOLOGY OF MS REMAINS UNKNOWN, THOUGH RECENT STUDIES HAVE POINTED TOWARDS A COMBINATION OF GENETIC AND ENVIRONMENTAL FACTORS. INTRIGUINGLY, A STRONG CORRELATION EXISTS BETWEEN PREVIOUS EXPOSURE TO EBSTEIN-BARR VIRUS, WHICH INCREASES THE RISK OF DEVELOPING MS BY 30-FOLD. AS THIS HIGHLIGHTS A POTENTIALLY IMPORTANT ROLE THAT VIRAL INFECTION MAY PLAY IN THE INITIATION OF MS, OUR LAB UTILIZES A MURINE NEUROTROPIC JHM STRAIN OF MOUSE HEPATITIS VIRUS (JHMV) THAT RESULTS IN AN ACUTE ENCEPHALOMYELITIS THAT IS ACCOMPANIED BY GRAY MATTER INVOLVEMENT WITH INFECTION OF OLIGODENDROCYTES, ASTROCYTES, AND MICROGLIA. JHMV PERSISTS IN THE WHITE MATTER TRACTS OF THE SPINAL CORD, INDUCING DEMYELINATION RESULTING IN HIND-LIMB PARALYSIS IN MICE. WE AND OTHERS HAVE DEMONSTRATED PREVIOUSLY THAT MICROGLIA, A RESIDENT INNATE IMMUNE CELL POPULATION THAT RESIDES IN THE CENTRAL NERVOUS SYSTEM (CNS), ARE CRITICAL IN CONSTRAINING THE IMMUNE RESPONSE IN DEMYELINATING MODELS OF MS. INTRIGUINGLY, IN AREAS OF DEMYELINATION UNDERGOING REMYELINATION, THERE IS A SIGNIFICANT UPREGULATION OF CYSTATIN F (CST7), A PROTEASE INHIBITOR. WHILE CST7 IS EXPRESSED ON MANY IMMUNE CELLS, WE'VE SHOWN THAT MICROGLIA ARE THE PREDOMINANT SOURCE OF CST7 IN THE BRAIN. THUS, THIS PROPOSAL SEEKS TO DEFINE THE ROLE OF MICROGLIA-DERIVED CST7 IN THE CONTEXT OF A VIRAL INFECTION WITH JHMV. WE PROPOSE TO INFECT NOVEL TRANSGENIC CONDITIONAL KNOCKOUT MICE FOR CST7 ON MICROGLIA AND WILD-TYPE ANIMALS WITH JHMV TO DETERMINE THE IMPACT OF CST7 ON THE IMMUNE RESPONSE. A COMBINATION OF FLOW CYTOMETRY AND IMAGING MODALITIES WILL BE UTILIZED TO CHARACTERIZE DIFFERENCES IN BRAIN IMMUNE CELL INFILTRATION AND ACTIVATION. THE IMPACT OF THE CONDITIONAL ABLATION OF CST7 ON DEMYELINATION AND SUBSEQUENT REMYELINATION WILL BE ASSESSED AS WELL, USING STATE-OF-THE-ART TECHNIQUES LIKE SPATIAL TRANSCRIPTOMICS (AIM 1). BASED ON OUR PRELIMINARY AND PUBLISHED FINDINGS, WE HYPOTHESIZE THAT CST7 EXPRESSED ON MICROGLIA IS HOST PROTECTIVE. THEREFORE, WE ALSO PROPOSE TO EVALUATE CST7 AS A POTENTIAL THERAPEUTIC FOR DEMYELINATING DISEASES BY EMPLOYING AN OVEREXPRESSION MODEL. CST7 WILL BE OVEREXPRESSED IN MICROGLIA IN MICE INFECTED WITH JHMV AND THE SUBSEQUENT IMMUNE RESPONSE AND MYELINATION STATUS WILL BE EVALUATED USING SIMILAR TECHNIQUES AS DESCRIBED ABOVE (AIM 2). TOGETHER, THESE AIMS SEEK TO EVALUATE THE ROLE OF MICROGLIA-DERIVED CST7 IN AN EFFORT TO FURTHER DELINEATE MECHANISMS OF DEMYELINATION AND REMYELINATION. AS IT IS EXTREMELY RARE FOR DAMAGED NEURONS TO UNDERGO REMYELINATION IN MS, DEFINING THESE MECHANISMS FURTHER WILL PROVIDE INVALUABLE INSIGHT FOR THE ADVANCEMENT OF NEW THERAPEUTICS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $75.1k | 7/16/25 |